bevantolol has been researched along with Hypertension in 16 studies
bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical efficacy and safety of bevantolol hydrochloride, a newly developed beta-blocker, used in combination with other types of antihypertensive agents, were evaluated in patients with severe hypertension by multicenter open-label trials." | 9.08 | Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. The Cooperative Study Group on Bevantolol in Japan. ( Arakawa, K; Iimura, O; Inagaki, Y; Ishii, M; Miura, Y; Noshiro, T; Saruta, T; Yamazaki, N; Yoshinaga, K, 1995) |
| "In patients with essential hypertension, the beta-blockers bevantolol or propranolol were administered once or twice a day for twelve weeks to evaluate the effects on blood pressure, and lipid metabolism." | 9.07 | Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension. ( Arakawa, K; Kajiyama, G; Koga, S; Kusukawa, R; Mori, H; Ogawa, N; Sasaki, J; Takagi, R; Tanaka, N, 1994) |
| "Two multicenter, double-blind, placebo-controlled studies were conducted to determine in patients with hypertension the oral dose of bevantolol that would effectively reduce home diastolic blood pressure to less than 95 mm Hg." | 9.06 | Effectiveness of bevantolol in the treatment of hypertension: once-daily versus twice-daily evaluation of home blood pressure measurements. ( Jain, A, 1986) |
| "In an international, randomized, double-blind trial involving 229 patients, 400 mg of bevantolol was compared with 100 mg of atenolol (both in single daily doses) in the management of mild to moderate hypertension (diastolic blood pressure [BP] 95 to 115 mm Hg after a 4-week placebo washout period)." | 9.06 | Comparison of bevantolol and atenolol for systemic hypertension. ( Fairhurst, GJ, 1986) |
| " The Study Group evaluated its therapeutic utility (100-300 mg bid) compared with propranolol (80-240 mg bid) in 266 patients with mild to moderate essential hypertension (WHO Grades I and II, sitting diastolic blood pressure (DBP) greater than or equal to 95 mmHg)." | 9.06 | Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension. ( Maclean, D, 1988) |
| "The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo." | 9.05 | Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension. ( Lucas, CP; Morledge, JH; Tessman, DK, 1985) |
| "Effects of chronic treatment with bevantolol, a beta-adrenoceptor blocker, and of repeated immobilization stress on blood pressure, body weight, and [3H]dihydroalprenolol ([3H]DHA) binding to the cerebral cortex were examined in rats." | 7.68 | Effects of bevantolol HCl on immobilization stress-induced hypertension and central beta-adrenoceptors in rats. ( Kigoshi, S; Muramatsu, I; Takita, M, 1993) |
| "The antihypertensive efficacy of bevantolol, a selective beta 1-adrenoreceptor antagonist, was evaluated in 17 patients with essential hypertension, using continuous ambulatory intraarterial blood pressure (BP) monitoring." | 7.67 | Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. ( Al-Khawaja, IM; Caruana, MP; Prince, H; Raftery, EB; Whittington, J, 1986) |
| "Bevantolol is a new beta-adrenoceptor antagonist which possesses a relatively high degree of selectivity for beta 1-adrenoceptors." | 6.37 | Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Benfield, P; Frishman, WH; Goldberg, RJ, 1988) |
| "The clinical efficacy and safety of bevantolol hydrochloride, a newly developed beta-blocker, used in combination with other types of antihypertensive agents, were evaluated in patients with severe hypertension by multicenter open-label trials." | 5.08 | Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. The Cooperative Study Group on Bevantolol in Japan. ( Arakawa, K; Iimura, O; Inagaki, Y; Ishii, M; Miura, Y; Noshiro, T; Saruta, T; Yamazaki, N; Yoshinaga, K, 1995) |
| "In patients with essential hypertension, the beta-blockers bevantolol or propranolol were administered once or twice a day for twelve weeks to evaluate the effects on blood pressure, and lipid metabolism." | 5.07 | Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension. ( Arakawa, K; Kajiyama, G; Koga, S; Kusukawa, R; Mori, H; Ogawa, N; Sasaki, J; Takagi, R; Tanaka, N, 1994) |
| "Two multicenter, double-blind, placebo-controlled studies were conducted to determine in patients with hypertension the oral dose of bevantolol that would effectively reduce home diastolic blood pressure to less than 95 mm Hg." | 5.06 | Effectiveness of bevantolol in the treatment of hypertension: once-daily versus twice-daily evaluation of home blood pressure measurements. ( Jain, A, 1986) |
| "In an international, randomized, double-blind trial involving 229 patients, 400 mg of bevantolol was compared with 100 mg of atenolol (both in single daily doses) in the management of mild to moderate hypertension (diastolic blood pressure [BP] 95 to 115 mm Hg after a 4-week placebo washout period)." | 5.06 | Comparison of bevantolol and atenolol for systemic hypertension. ( Fairhurst, GJ, 1986) |
| " The Study Group evaluated its therapeutic utility (100-300 mg bid) compared with propranolol (80-240 mg bid) in 266 patients with mild to moderate essential hypertension (WHO Grades I and II, sitting diastolic blood pressure (DBP) greater than or equal to 95 mmHg)." | 5.06 | Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension. ( Maclean, D, 1988) |
| "The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo." | 5.05 | Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension. ( Lucas, CP; Morledge, JH; Tessman, DK, 1985) |
| "Effects of chronic treatment with bevantolol, a beta-adrenoceptor blocker, and of repeated immobilization stress on blood pressure, body weight, and [3H]dihydroalprenolol ([3H]DHA) binding to the cerebral cortex were examined in rats." | 3.68 | Effects of bevantolol HCl on immobilization stress-induced hypertension and central beta-adrenoceptors in rats. ( Kigoshi, S; Muramatsu, I; Takita, M, 1993) |
| "The antihypertensive efficacy of bevantolol, a selective beta 1-adrenoreceptor antagonist, was evaluated in 17 patients with essential hypertension, using continuous ambulatory intraarterial blood pressure (BP) monitoring." | 3.67 | Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. ( Al-Khawaja, IM; Caruana, MP; Prince, H; Raftery, EB; Whittington, J, 1986) |
| "Bevantolol was well tolerated." | 2.66 | Dose response studies of bevantolol in hypertensive patients. ( Okawa, KK, 1986) |
| " The drug was associated with a low incidence of adverse experiences similar to that observed with placebo." | 2.66 | Safety profile of bevantolol. ( Bray, JS, 1986) |
| "Bevantolol is a new beta-adrenoceptor antagonist which possesses a relatively high degree of selectivity for beta 1-adrenoceptors." | 2.37 | Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Benfield, P; Frishman, WH; Goldberg, RJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (81.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noshiro, T | 1 |
| Miura, Y | 1 |
| Yoshinaga, K | 1 |
| Iimura, O | 1 |
| Inagaki, Y | 1 |
| Saruta, T | 1 |
| Ishii, M | 1 |
| Yamazaki, N | 1 |
| Arakawa, K | 2 |
| Sasaki, J | 1 |
| Kajiyama, G | 1 |
| Kusukawa, R | 1 |
| Mori, H | 1 |
| Koga, S | 1 |
| Takagi, R | 1 |
| Tanaka, N | 1 |
| Ogawa, N | 1 |
| Takita, M | 1 |
| Kigoshi, S | 1 |
| Muramatsu, I | 1 |
| Fernandez, PG | 2 |
| Snedden, W | 2 |
| Vasdev, S | 1 |
| Bolli, P | 1 |
| Lucas, CP | 1 |
| Morledge, JH | 1 |
| Tessman, DK | 1 |
| Okawa, KK | 1 |
| Jain, A | 1 |
| Bray, JS | 1 |
| Al-Khawaja, IM | 1 |
| Caruana, MP | 1 |
| Prince, H | 1 |
| Whittington, J | 1 |
| Raftery, EB | 1 |
| Fairhurst, GJ | 1 |
| Nath, C | 1 |
| Frishman, WH | 1 |
| Goldberg, RJ | 1 |
| Benfield, P | 1 |
| Maclean, D | 1 |
| Bompart, J | 1 |
| Pastor, G | 1 |
| Giral, L | 1 |
| Alvart, R | 1 |
1 review available for bevantolol and Hypertension
| Article | Year |
|---|---|
Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Humans; Hypertension; Propanolamines | 1988 |
11 trials available for bevantolol and Hypertension
| Article | Year |
|---|---|
Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. The Cooperative Study Group on Bevantolol in Japan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Chemical Analysis; Blood Pressure; Body Weight; Diur | 1995 |
Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apolipoproteins; Blood Pressure; Fatty Acids, Nonesterifie | 1994 |
Bevantolol attenuates thiazide stimulated renin secretion and catecholamine release in diuretic resistant hypertensives.
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Adult; Catecholamines; Drug Therapy, Combination; Femal | 1989 |
Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1985 |
The use of beta-adrenergic blockers in the treatment of angina and hypertension. A clinical symposium. 31st annual meeting, American College of Angiology and 21st annual meeting, International College of Angiology. San Antonio, Texas, November 6, 1984.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Clinical Trials as Topic; Humans; Hypertensio | 1986 |
Dose response studies of bevantolol in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, D | 1986 |
Effectiveness of bevantolol in the treatment of hypertension: once-daily versus twice-daily evaluation of home blood pressure measurements.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Blood Pressure Determination; Double-Blind Method; Drug | 1986 |
Safety profile of bevantolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Clinical Trials as Topic; Double | 1986 |
Comparison of bevantolol and atenolol for systemic hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Double-Blind Method; Female; Heart Rate; Humans; Hypertension | 1986 |
The blood pressure responses of thiazide-resistant hypertensives to a once-a-day bevantolol regimen.
Topics: Adrenergic beta-Antagonists; Adult; Benzothiadiazines; Blood Pressure; Diuretics; Drug Administratio | 1987 |
Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1988 |
4 other studies available for bevantolol and Hypertension
| Article | Year |
|---|---|
Effects of bevantolol HCl on immobilization stress-induced hypertension and central beta-adrenoceptors in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Cerebral Cortex; Dihydroalprenolo | 1993 |
A symposium: Bevantolol--a new cardiovascular agent with a unique profile. April 21, 1985, Geneva, Switzerland.
Topics: Adrenergic beta-Antagonists; Animals; Heart Diseases; Humans; Hypertension; Propanolamines | 1986 |
Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure Determination; Circadian Rhythm; Drug Admin | 1986 |
[Synthesis of new beta-blockaders analogs of bevantolol or alprenolol].
Topics: Adrenergic beta-Antagonists; Alprenolol; Chemical Phenomena; Chemistry; Hypertension; Propanolamines | 1987 |